Patents Examined by John Rollins
  • Patent number: 4867979
    Abstract: Antidiarrheal compositions showing enhanced antidiarrheal activity comprise a non-steroidal anti-inflammatory drug compound and a polymeric hydroabsorptive agent. A patient in need of remedial or preventive treatment of diarrhea symptoms is administered an antidiarrheally effective amount of said antidiarrheal compositions.
    Type: Grant
    Filed: September 30, 1986
    Date of Patent: September 19, 1989
    Assignee: Richardson-Vicks Inc.
    Inventors: Bhogilal B. Sheth, Sheri A. Gilbert, Jane F. Kinsel
  • Patent number: 4820516
    Abstract: The hyaluronidase, which is a hyaluronic acid-specific endo-.beta.-glucuronidase, having a molecular weight of about 28,500 in non-reduced form, is derived from buffalo leeches (that is, leeches of the sub-family Hirudinariinae, such as the species Hirudinaria manillensis or Poecilobdella granulosa).The hyaluronidase, which cleaves hyaluronic acid, but not chondroitin, chondroitin -4- sulphate, chondroitin -6- sulphate or heparin, is considerably more stable at high temperatures and extremes of pH than known leech hyaluronidase. It has a wide range of uses where breakdown of hyaluronic acid is required; of particular interest is in pharmaceutical or veterinary formulations, either as an active agent or a spreading or percutaneous factor. The hyaluronidase is useful for stimulating flow of physiological fluids in the eye (for example, in the treatment of glaucoma).
    Type: Grant
    Filed: February 14, 1986
    Date of Patent: April 11, 1989
    Assignee: Biopharm (UK) Limited
    Inventors: Roy T. Sawyer, Jeffrey Edwards
  • Patent number: 4818816
    Abstract: The invention relates to a process for the organic synthesis of oligosaccharides constituting or comprising fragments of acid mucopolysaccharides comprising the reaction of two compounds constituted or terminated by units of glucosamine structure and of uronic acid structure respectively, said units being specifically substituted. This process particularly enables valuable anticoagulant drugs to be obtained.
    Type: Grant
    Filed: October 26, 1987
    Date of Patent: April 4, 1989
    Assignee: Choay, S.A.
    Inventors: Maurice Petitou, Jean-Claude Jacquinet, Pierre Sinay, Jean Choay, Jean-Claude Lormeau, Mahmoud Nassr
  • Patent number: 4816462
    Abstract: A method of diagnosing and for therapeutic treatment of tumors and of infectious diseases by administering effective amounts of cytostatic compositions of alkaloid compounds, their derivatives, salts of the alkaloid compounds, salts of said derivatives or mixtures thereof. The alkaloid component causes stimulation of the cellular defense mechanism, exhibits a great affinity for tumor cells with rapid accumulation in the tumor cells, interferes with cellular activity of tumor cells and cells attacked by virus and other antigens, and destroys malignant tumors and other antigen structures such as viruses, bacteria, fungal organisms. The alkaloid component can be unlabelled or labelled with radioactive isotopes. The compositions may contain materials which are fluorescent under U.V. light or compounds which absorb X-rays. In addition, the compositions can be used as an analgesic in the treatment of polyarthritis and as post-operative anti-inflammation reagent.
    Type: Grant
    Filed: February 20, 1986
    Date of Patent: March 28, 1989
    Inventor: Wassyl Nowicky
  • Patent number: 4816446
    Abstract: The invention comprises heparin derivative compounds which possess a low density lipoprotein lowering action without a significant anticoagulent effect, and are therefore useful in the treatment of disturbances of fat metabolism, especially hyperlipidemia. The heparin derivatives of the invention are derived from natural heparin, and are prepared by the hydrolysis of heparin and optionally, subsequent acylation at free amine groups of the hydrolyzed heparin.
    Type: Grant
    Filed: June 13, 1985
    Date of Patent: March 28, 1989
    Assignee: Intermedicat GmbH
    Inventors: Wolfgang Feller, Rainer Stormer, Annemarie Muller
  • Patent number: 4800081
    Abstract: The disclosure demonstrates the inhibition of replication of human cytomegalovirus (HCMV) in cultured human embryo skin muscle cells by two separate subclasses of direct-acting smooth muscle relaxing agents alone or in combination with each other. These two subclasses are characterized mechanistically as calcium influx blockers (or calcium channel blockers) and cyclic nucleotide modulators. More specifically, the class of calcium influx blockers is exemplified by the drugs verapamil (and methoxyverapamil), nifedipine (the prototype drug of 1,4 dihydropyridines), and diltiazem. The class of cyclic nucleotide modulators is exemplified by the drugs isobutylmethlyxanthine, papaverine (and its synthetic analog dioxyline), forskolin, and sodium nitroprusside. In addition, the present disclosure demonstrates that agents from one class, e.g., a calcium influx blocker, act synergistically when used in combination with agents from the other class, e.g., cyclic nucleotide modulators.
    Type: Grant
    Filed: June 5, 1986
    Date of Patent: January 24, 1989
    Assignee: Board of Regents, The University of Texas System
    Inventors: Thomas Albrecht, Chan H. Lee
  • Patent number: 4795636
    Abstract: A method for treating herpes simplex virus is disclosed in which a sufferer is treated with garlic or a garlic preparation such as a health food mixture containing such garlic extract or the active ingredient of the garlic. The treatment can be done either orally or topically, and the treatment delays and minimizes the symptoms of the virus, as well as increasing the period of time between recurrences of viral shedding.
    Type: Grant
    Filed: November 20, 1985
    Date of Patent: January 3, 1989
    Inventor: Julia J. Tsuei
  • Patent number: 4791195
    Abstract: Novel oligosaccharide fractions with valuable pharmacological properties are obtained from heparin. They have the same structural characteristics of heparin. The heparin fraction consists of oligosaccharides which contain end groups consisting of iduronic acid 2-sulfate, or glucosamine N, 6-disulfate. Further the oligosaccharides contain and monosaccharide endowed with reducing anomeric carbon, and are constituted by multiples of monosaccharide units.
    Type: Grant
    Filed: October 21, 1986
    Date of Patent: December 13, 1988
    Assignee: Opocrin A.P.A.
    Inventors: Pietro Bianchini, Giuseppe Mascellani
  • Patent number: 4788302
    Abstract: A tissue extract containing a low molecular weight, non-proteinaceous compound selected from the group consisting of (A) methanol-soluble compounds obtainable from Leptogorgia virgulata with R.sub.f values in reverse-phase, thin layer, silica gel chromatography of (1) 0.42, 0.54, and 0.62; (2) 0.35, 0.50, and 0.58; (3) 0.37, 0.47, and 0.58; or (4) 0.31, 0.43, and 0.54, respectively, in 1:1:1 methanol:ethyl acetate:water, 2:1:1 methanol:ethyl acetate:water, and 1:2:1 methanol:ethyl acetate:water, or (B) methanol-soluble compounds obtainable from Renilla reinformis with R.sub.f values in thin layer, silica gel chromatography of (1) 0:44, 0.37, and 0.53; (2) 0.52, 0.42, and 0.60; (3) 0.56, 0.43, and 0.63; or (4) 0.32, 0.26, and 0.37, respectively, in 9:1 chloroform:acetonitrile, 9:1 methylene chloride:acetonitrile, and 4:1 methylene chloride:acetonitrile and compositions containing the same, which is useful as antifouling compositions, is disclosed.
    Type: Grant
    Filed: January 31, 1986
    Date of Patent: November 29, 1988
    Assignee: Duke University
    Inventors: John D. Costlow, Irving R. Hooper, Daniel Rittschof
  • Patent number: 4786497
    Abstract: Improved camomile extracts are obtained by extraction of fresh camomile flowers with aqueous lower alkanols and wthout a subsequent heat treatment.
    Type: Grant
    Filed: September 8, 1987
    Date of Patent: November 22, 1988
    Assignee: Degussa Aktiengesellschaft
    Inventors: Otto Isaac, Reinhold Carle
  • Patent number: 4786496
    Abstract: An immunopotentiator having an anti-tumor activity such as an effect for inhibiting the growth of tumor cells, an effect for prolonging the death by tumor, etc. is provided, which agent contains as its active ingredient, the lipid fraction or the glycolipid fraction of a marine chlorella such as Chlorella minutissima or Chlorella vulgaris, the lipid fraction being obtained e.g. by extracting a marine chlorella with an organic solvent, and the glycolipid fraction, e.g. by separating it from the lipid fraction with a mixed solvent according to silica gel chromatography.
    Type: Grant
    Filed: February 18, 1986
    Date of Patent: November 22, 1988
    Assignee: The Nisshin Oil Mills, Ltd.
    Inventors: Souichirou Watanabe, Tadasu Fujita
  • Patent number: 4784853
    Abstract: An antiviral agent containing as its active ingredient, an ingredient extracted from Crocosmia x crocosmaeflora N.E. Br.
    Type: Grant
    Filed: May 4, 1987
    Date of Patent: November 15, 1988
    Assignee: Chisso Corporation
    Inventors: Takeshi Inoi, Hiroaki Ishibashi, Etsuro Yoshikawa
  • Patent number: 4783457
    Abstract: The invention relates to an invertebrate pest controlling composition comprising an invertebrate pest-controlling amount of a non-formamidine octopamine against having substantial activity toward an octopamine receptor present in an invertebrate pest and a pesticidally inert carrier.
    Type: Grant
    Filed: March 17, 1987
    Date of Patent: November 8, 1988
    Assignee: The General Hospital Corporation
    Inventor: James A. Nathanson
  • Patent number: 4782065
    Abstract: The disclosure demonstrates the inhibition of replication of human cytomegalovirus (HCMV) in cultured human embryo skin muscle cells by two separate subclasses of direct-acting smooth muscle relaxing agents. These two subclasses are characterized mechanistically as calcium influx blockers (or calcium channel blockers) and cyclic nucleotide modulators. More specifically, the class of calcium influx blockers is exemplified by the drugs verapamil (and methoxyverapamil), nifedipine (the prototype drug of 1,4 dihydropyridines), and diltiazem. The class of cyclic nucleotide modulators is exemplified by the drugs isobutylmethylxanthine, papaverine (and its synthetic analog dioxyline), forskolin, and sodium nitroprusside. All of these agents inhibit replication of HCMV and HSV.
    Type: Grant
    Filed: January 13, 1987
    Date of Patent: November 1, 1988
    Assignee: Board of Regents, The University of Texas System
    Inventors: Thomas Albrecht, Odd S. Steinsland
  • Patent number: 4780314
    Abstract: This invention relates to a novel recovery process for obtaining the small molecular weight, digitalis-like factor, and further relates to purification of the digitalis-like factor. This invention also relates to the identification and characterization of the factor and to therapeutic uses for the purified factor.
    Type: Grant
    Filed: October 30, 1985
    Date of Patent: October 25, 1988
    Assignee: Brigham and Women's Hospital
    Inventor: Steven W. Graves
  • Patent number: 4780453
    Abstract: Treatment of cats carrying or infected with the Feline Leukemia virus or having antibodies to the Feline leukemia virus is disclosed using the compound 3'-azido''-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: December 23, 1986
    Date of Patent: October 25, 1988
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
  • Patent number: 4778787
    Abstract: Angiogenesis healing factors residing in omentum-derived lipid fractions with or without gangliosides or their synthetic equivalents can be used to treat myocardial ischemic conditions including but not limited to myocardial infarction, angina, as well as in heart transplant, vascular grafts, and re-opened vessels leading to improved vascularization, perfusion, collagenization and organization of said lesions; the involved and adjacent tissues.
    Type: Grant
    Filed: December 20, 1985
    Date of Patent: October 18, 1988
    Assignees: Trustees of Boston University, Angio-Medical Corporation
    Inventors: Nicholas Catsimpoolas, Haralambos Gavras, Christian C. Haudenschild, Michael I. Klibaner
  • Patent number: 4778766
    Abstract: A testing agent for neutrophil function includes a substance having a molecular weight of 5,000 or more. The substance is contained in an extract extracted from chlorella alga using an aqueous solvent. The agent activates neutrophils specifically.
    Type: Grant
    Filed: September 5, 1985
    Date of Patent: October 18, 1988
    Assignee: Chlorella Industry Co., Ltd.
    Inventors: Kuniaki Tanaka, Fumiko Konishi
  • Patent number: 4777161
    Abstract: The medicaments of the invention contain in their active principle, oligosaccharides of low molecular weight corresponding to or including heparin fragments.
    Type: Grant
    Filed: May 29, 1985
    Date of Patent: October 11, 1988
    Assignee: Choay S.A.
    Inventors: Jean-Claude Lormeau, Maurice Petitou, Jean Choay, Francis Toulemonde
  • Patent number: 4777166
    Abstract: This invention relates to various compositions, comprising a 2-acetylprid thiosemicarbazone and a diol, which are useful in the treatment of viral infections.
    Type: Grant
    Filed: March 31, 1986
    Date of Patent: October 11, 1988
    Assignees: The United States of America as represented by the Secretary of the Army, The Regents of The University of Michigan
    Inventors: Sandra H. Smith, John C. Drach, Gordon L. Flynn